Latest Posts

The blurring of medical niches

Market segmentation may mean little to patients. They matter a lot to investors, to venture capitalists, and to market participants. As nanotechnology seeks its market, these distinctions are going to get blurrier still.

August 31, 2007 by Dana Blankenhorn

Comments

Today's Debate: Is medical tech growth good?

The immense size of the U.S. market has made it a magnet for new technologies from around the world, but costs and benefits are not often considered. To what extent is this responsible for our industry's "robust" growth, and is that really a good thing?

August 31, 2007 by Dana Blankenhorn

Comments